CA1093962A - Dosage competitif des acides biliaires a l'aide d'un inhibiteur de liaison des proteines - Google Patents

Dosage competitif des acides biliaires a l'aide d'un inhibiteur de liaison des proteines

Info

Publication number: CA1093962A
Authority: CA; Canada
Prior art keywords: bile acid; acid; assay; bile; antiserum
Prior art date: 1978-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA324,498A

Other languages

English (en)

Inventor

Phillip C. Miller

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-04-26

Filing date

1979-03-30

Publication date

1981-01-20

1979-03-30 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

1981-01-20 Application granted granted Critical

1981-01-20 Publication of CA1093962A publication Critical patent/CA1093962A/fr

Status Expired legal-status Critical Current

Links

239000003613 bile acid Substances 0.000 title claims abstract description 55
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title claims abstract description 32
230000027455 binding Effects 0.000 title claims abstract description 11
238000009739 binding Methods 0.000 title claims abstract description 11
102000004169 proteins and genes Human genes 0.000 title abstract description 11
108090000623 proteins and genes Proteins 0.000 title abstract description 11
238000012875 competitive assay Methods 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
238000003556 assay Methods 0.000 claims abstract description 30
238000000034 method Methods 0.000 claims abstract description 25
239000003795 chemical substances by application Substances 0.000 claims abstract description 12
102000014914 Carrier Proteins Human genes 0.000 claims abstract description 8
108091008324 binding proteins Proteins 0.000 claims abstract description 8
230000002401 inhibitory effect Effects 0.000 claims abstract description 8
210000002966 serum Anatomy 0.000 claims description 36
239000000203 mixture Substances 0.000 claims description 11
239000000376 reactant Substances 0.000 claims description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
230000006872 improvement Effects 0.000 claims description 7
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 claims description 6
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 5
239000004380 Cholic acid Substances 0.000 claims description 5
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 5
229960002471 cholic acid Drugs 0.000 claims description 5
235000019416 cholic acid Nutrition 0.000 claims description 5
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 5
238000002372 labelling Methods 0.000 claims description 5
230000014759 maintenance of location Effects 0.000 claims description 5
229960001860 salicylate Drugs 0.000 claims description 5
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 4
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical group [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 4
238000001514 detection method Methods 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
229960004025 sodium salicylate Drugs 0.000 claims description 4
229960002319 barbital Drugs 0.000 claims description 3
AXDXVEYHEODSPN-HVATVPOCSA-N lithocholic acid sulfate Chemical compound C([C@H]1CC2)[C@H](OS(O)(=O)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 AXDXVEYHEODSPN-HVATVPOCSA-N 0.000 claims 4
RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 claims 1
238000000605 extraction Methods 0.000 abstract description 6
239000013060 biological fluid Substances 0.000 abstract description 5
230000002452 interceptive effect Effects 0.000 abstract description 3
108010071390 Serum Albumin Proteins 0.000 abstract description 2
102000007562 Serum Albumin Human genes 0.000 abstract description 2
238000005259 measurement Methods 0.000 abstract description 2
102400001066 Growth hormone-binding protein Human genes 0.000 abstract 1
101800000194 Growth hormone-binding protein Proteins 0.000 abstract 1
108010007979 Glycocholic Acid Proteins 0.000 description 29
RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 29
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 29
238000003127 radioimmunoassay Methods 0.000 description 25
238000012360 testing method Methods 0.000 description 12
239000000872 buffer Substances 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
239000000243 solution Substances 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
108010017384 Blood Proteins Proteins 0.000 description 7
102000004506 Blood Proteins Human genes 0.000 description 7
239000000562 conjugate Substances 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
230000009871 nonspecific binding Effects 0.000 description 6
239000000700 radioactive tracer Substances 0.000 description 6
238000011084 recovery Methods 0.000 description 6
210000000941 bile Anatomy 0.000 description 5
238000003018 immunoassay Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000003858 bile acid conjugate Substances 0.000 description 3
210000001198 duodenum Anatomy 0.000 description 3
108010074605 gamma-Globulins Proteins 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
239000012847 fine chemical Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
210000000232 gallbladder Anatomy 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
229940027941 immunoglobulin g Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
-1 sulfolithocholic Chemical compound 0.000 description 2
239000010414 supernatant solution Substances 0.000 description 2
229960003080 taurine Drugs 0.000 description 2
238000010998 test method Methods 0.000 description 2
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
229940033663 thimerosal Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000007982 barbital buffer Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
GHAFORRTMVIXHS-UHFFFAOYSA-L bromosulfophthalein sodium Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(O)=CC=C1C1(C=2C=C(C(O)=CC=2)S([O-])(=O)=O)C(C(Br)=C(Br)C(Br)=C2Br)=C2C(=O)O1 GHAFORRTMVIXHS-UHFFFAOYSA-L 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
230000004087 circulation Effects 0.000 description 1
210000001953 common bile duct Anatomy 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000010235 enterohepatic circulation Effects 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001030 gas--liquid chromatography Methods 0.000 description 1
229930182480 glucuronide Natural products 0.000 description 1
150000008134 glucuronides Chemical class 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000024557 hepatobiliary disease Diseases 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
FHXBAFXQVZOILS-OETIFKLTSA-N sulfoglycolithocholic acid Chemical compound C([C@H]1CC2)[C@H](OS(O)(=O)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 FHXBAFXQVZOILS-OETIFKLTSA-N 0.000 description 1
108700018664 sulfolithocholylglycine Proteins 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA324,498A 1978-04-26 1979-03-30 Dosage competitif des acides biliaires a l'aide d'un inhibiteur de liaison des proteines Expired CA1093962A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89991878A	1978-04-26	1978-04-26
US899,918		1978-04-26

Publications (1)

Publication Number	Publication Date
CA1093962A true CA1093962A (fr)	1981-01-20

Family

ID=25411734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA324,498A Expired CA1093962A (fr)	1978-04-26	1979-03-30	Dosage competitif des acides biliaires a l'aide d'un inhibiteur de liaison des proteines

Country Status (11)

Country	Link
JP (1)	JPS54149700A (fr)
AU (1)	AU527381B2 (fr)
BE (1)	BE875854A (fr)
CA (1)	CA1093962A (fr)
DE (1)	DE2916783C3 (fr)
ES (1)	ES479985A1 (fr)
FR (1)	FR2424536A1 (fr)
GB (1)	GB2020014B (fr)
IT (1)	IT1112580B (fr)
NL (1)	NL7902396A (fr)
SE (1)	SE7903645L (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5474907A (en) *	1994-03-25	1995-12-12	Eastman Kodak Company	Multilayer analytical element for salicylate assay
JP2638521B2 (ja) *	1994-11-24	1997-08-06	有限会社ビー・エス・アール	Ｅｌｉｓａによる血清中胆汁酸類の測定による肝疾患決定法
JP6602952B2 (ja) *	2016-02-29	2019-11-06	富士フイルム株式会社	生体試料中の胆汁酸を定量するためのキット及び生体試料中の胆汁酸を定量する方法
WO2017150517A1 (fr) *	2016-02-29	2017-09-08	富士フイルム株式会社	Kit pour déterminer la quantité de substance à analyser dans un échantillon biologique
CN106501535B (zh) *	2016-11-30	2018-11-09	迪瑞医疗科技股份有限公司	一种ans盐复合释放剂与检测血液中皮质醇的试剂盒
CN109444399A (zh) *	2018-10-26	2019-03-08	重庆中元汇吉生物技术有限公司	一种甘胆酸检测试剂盒
CN113721012B (zh) *	2021-08-27	2022-08-09	深圳上泰生物工程有限公司	一种组合物及其试剂盒在检测甘胆酸中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1050425A (fr) *	1975-06-26	1979-03-13	Mallinckrodt	Dosage radioimmunologique de la l-triiodothyronine et de la thyroxine
JPS5851000B2 (ja) *	1976-04-16	1983-11-14	アボツトラボラトリ−ズ	スルホリトコリルグリシルチラミンの製造法

1979
- 1979-03-27 NL NL7902396A patent/NL7902396A/xx not_active Application Discontinuation
- 1979-03-30 CA CA324,498A patent/CA1093962A/fr not_active Expired
- 1979-03-30 AU AU45634/79A patent/AU527381B2/en not_active Ceased
- 1979-04-05 GB GB7911887A patent/GB2020014B/en not_active Expired
- 1979-04-24 FR FR7910391A patent/FR2424536A1/fr active Pending
- 1979-04-24 JP JP4984979A patent/JPS54149700A/ja active Pending
- 1979-04-24 IT IT22140/79A patent/IT1112580B/it active
- 1979-04-25 BE BE0/194838A patent/BE875854A/fr not_active IP Right Cessation
- 1979-04-25 DE DE2916783A patent/DE2916783C3/de not_active Expired
- 1979-04-25 SE SE7903645A patent/SE7903645L/ not_active Application Discontinuation
- 1979-04-26 ES ES479985A patent/ES479985A1/es not_active Expired

Also Published As

Publication number	Publication date
IT7922140A0 (it)	1979-04-24
IT1112580B (it)	1986-01-20
AU4563479A (en)	1979-11-01
DE2916783A1 (de)	1979-10-31
AU527381B2 (en)	1983-03-03
ES479985A1 (es)	1980-08-16
DE2916783C3 (de)	1982-04-01
NL7902396A (nl)	1979-10-30
SE7903645L (sv)	1979-10-27
BE875854A (fr)	1979-10-25
JPS54149700A (en)	1979-11-24
DE2916783B2 (de)	1981-07-16
GB2020014A (en)	1979-11-07
FR2424536A1 (fr)	1979-11-23
GB2020014B (en)	1982-10-20

Legal Events

Date	Code	Title	Description
1998-01-20	MKEX	Expiry

Publication	Publication Date	Title
EP0108400B1 (fr)	1987-04-29	Détermination de sites de liaisons non saturées thyroxine-protéine utilisant des techniques de polarisation de fluorescence
AU2005203321A1 (en)	2006-02-23	Assay
EP2823304B1 (fr)	2018-03-14	Système d'analyse intercalé pour médicaments immunosuppresseurs
EP3368900B1 (fr)	2020-12-23	Dosage en sandwich pour petites molécules
Ito et al.	1999	Simultaneous determination of alpha-fetoprotein, human chorionic gonadotropin and estriol in serum of pregnant women by time-resolved fluoroimmunoassay
Oda et al.	2001	Determination of bufalin-like immunoreactivity in serum of humans and rats by time-resolved fluoroimmunoassay for using a monoclonal antibody
US4452903A (en)	1984-06-05	Assay method and reagent kit means for lipid-containing body fluid
Miller et al.	1981	Specific 125I-radioimmunoassay for cholyglycine, a bile acid, in serum.
EP0104926A2 (fr)	1984-04-04	Méthode d'essai et composants utilisés pour cette méthode
EP0992512B1 (fr)	2005-12-14	Conjugué de cortisol réduit
Osman et al.	1995	A sensitive time-resolved immunofluorometric assay for the measurement of apolipoprotein B in cerebrospinal fluid. Application to multiple sclerosis and other neurological diseases
CA1299984C (fr)	1992-05-05	Methode pour la mesure des ligands libres dans des liquides biologiques, et essai pour cette mesure
US4347058A (en)	1982-08-31	Thyroid polarization fluoroimmunoassay
Mitchell et al.	2009	Matrix effects on an antigen immobilized format for competitive enzyme immunoassay of salivary testosterone
Dechaud et al.	1988	New approach to competitive lanthanide immunoassay: time-resolved fluoroimmunoassay of progesterone with labeled analyte.
CN107002017B (zh)	2020-07-28	疏水性半抗原分析物的精确测定测量
Kuemmerle et al.	1992	Automated assay of vitamin B-12 by the Abbott IMx® analyzer
US4226847A (en)	1980-10-07	Latex polymer sensitized with steroid-serum albumin conjugate, preparation and test therewith
HU228077B1 (en)	2012-10-29	Cobalamin assay
Thomson et al.	1989	A 125I-radioimmunoassay for measuring androstenedione in serum and in blood-spot samples from neonates.
HOSODA et al.	1981	A direct enzyme immunoassay of 6β-hydroxycortisol in human urine
EP2742352B1 (fr)	2018-02-28	Détection de stéroïdes sexuels
US5601993A (en)	1997-02-11	Anti-bile acid antibodies and method for assaying bile acids in feces by using the same
JP2009522581A (ja)	2009-06-11	競合免疫アッセイによるｆｋ７７８の濃度の決定
Teni et al.	1989	Prostatic inhibin-like peptide quantified in urine of prostatic cancer patients by enzyme-linked immunosorbent assay.